RJA
OREX

Raymond James & Associates’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Raymond James & Associates’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-8,647
Closed -$37K – 3386
2016
Q2 		$37K Buy
8,647
+400
+5% +$1.81K ﹤0.01% 2900
2016
Q1 		$46K Buy
+8,247
New +$107K ﹤0.01% 2793
2015
Q4 		– Sell
-10,297
Closed -$217K – 2470
2015
Q3 		$217K Buy
10,297
+300
+3% +$10.3K ﹤0.01% 2239
2015
Q2 		$495K Sell
9,997
-356
-3% -$21.3K ﹤0.01% 2094
2015
Q1 		$811K Buy
+10,353
New +$642K ﹤0.01% 1787
2014
Q3 		– Sell
-4,050
Closed -$250K – 2323
2014
Q2 		$250K Sell
4,050
-119
-3% -$6.92K ﹤0.01% 2108
2014
Q1 		$271K Buy
4,169
+155
+4% +$10.5K ﹤0.01% 1989
2013
Q4 		$226K Sell
4,014
-180
-4% -$10.1K ﹤0.01% 1930
2013
Q3 		$257K Sell
4,194
-116
-3% -$7.86K ﹤0.01% 1831
2013
Q2 		$252K Buy
+4,310
New +$265K ﹤0.01% 1775

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Raymond James & Associates's OREX Position: Q3 2016 in Review

Raymond James & Associates sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2016, closing a stake of 8,647 shares — an estimated $37K sold.

Raymond James & Associates first reported a position in OREX in Q2 2013 and held it in 10 quarters. The position peaked at $811K in Q1 2015. 55 funds tracked by Wall St. Rank hold OREX as of Q3 2016.

  • Raymond James & Associates reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Raymond James & Associates sold 8,647 Orexigen Therapeutics, Inc. shares in Q3 2016, an estimated $37K.
  • Raymond James & Associates first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 10 quarters.
  • Raymond James & Associates's Orexigen Therapeutics, Inc. position peaked at $811K in Q1 2015.
  • 55 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2016.

Based on Raymond James & Associates's 13F filing for Q3 2016, filed 14 Nov 2016.